Pathfinders in Biopharma Podcast
1) MindMed: Rethinking brain health with psychedelic therapy
Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the tre...Show More
2) Funding the future of retinal health with Eyepoint
Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.
3) How Blackstone Life Sciences is bridging the innovation gap
Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in thre...Show More
4) Compass trials mark a milestone moment for the psychedelics sector
Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale...Show More
5) Cidara’s pursuit of universal flu protection with a single dose
Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. Cidara Therapeutics believes it may have a better alternative. President and CEO Jeff Stei...Show More
6) Ocular Therapeutix’ bold vision to redefine retinal disease treatment
Pravin Dugel, CEO of Ocular Therapeutix provides insights into existing treatments and future product candidates for retinal diseases, underlining the unique challenges, opportunities and innovations ...Show More
7) PTC Therapeutics: Building a durable company to benefit patients
A surgeon in burns reconstruction, Matt Klein swapped the operating room for the equally high-pressure environment of drug development. In this episode of Pathfinders in Biopharma, he sets out the vis...Show More
8) BioAge is translating insights from the science of aging into new medicines
Scott Neidhold, Director in RBC’s Life Sciences Investment Banking Practice, sits down with Kristen Fortney, CEO and Co-Founder of BioAge, for a deep dive into how her company is turning cutting-edge ...Show More
9) Uncertainty reigns, but opportunity persists for biotech’s 2025
Universal wisdom had it that a Republican sweep in the U.S. election would favor biotech. Appointments to the new administration’s healthcare leadership make that far less certain. What effect will th...Show More
10) Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments
Innovation is surging in the U.S biotechnology sector, so why are investors still fearful about committing? Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, is joined ...Show More